With Celgene Acquisition Closed, Bristol Faces Major Milestones
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
Astounding plaintiffs, Celgene has backed out of a $55m settlement of a class-action lawsuit which accused the company of monopolizing the market for two top-selling cancer drugs and depriving patients of cheaper generic versions.
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.